MIRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mirum Pharmaceuticals Inc (MIRM) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company shows strong revenue growth and positive analyst sentiment, the technical indicators suggest a bearish trend, and the lack of recent positive news or significant trading signals makes it prudent to hold off on buying for now. The investor's impatience and unwillingness to wait for optimal entry points further support a cautious approach.
The MACD is negative and expanding (-2.44), indicating bearish momentum. RSI is at 29.599, in the neutral zone but leaning towards oversold territory. Moving averages are converging, suggesting indecision in price movement. The stock is trading below key pivot levels (Pivot: 97.973, S1: 89.692, S2: 84.575), indicating potential further downside.
Strong revenue growth in Q4 2025 (+49.81% YoY). Analysts have raised price targets significantly, with multiple firms maintaining 'Buy' or 'Outperform' ratings. Upcoming pivotal readouts in Primary Sclerosing Cholangitis and hepatitis delta virus could expand the company's hepatology franchise and unlock long-term value.
Net income and EPS have significantly declined (-75.91% and -77.55% YoY, respectively). No recent news or significant insider/hedge fund activity. Technical indicators suggest bearish momentum, and the stock is trading below key support levels.
In Q4 2025, revenue increased by 49.81% YoY to $148.93M, showcasing strong growth. However, net income dropped by 75.91% YoY to -$5.73M, and EPS declined by 77.55% YoY to -0.11. Gross margin improved to 81.02%, up 5.10% YoY, reflecting operational efficiency despite profitability challenges.
Analysts are overwhelmingly positive, with multiple firms raising price targets (ranging from $115 to $132) and maintaining 'Buy' or 'Outperform' ratings. Analysts highlight strong commercial momentum, durable growth in Livmarli and bile acid medicine, and upcoming catalysts as key drivers for long-term value.
